Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanhuo Decoction in Acute Coronary Syndrome Combined With Cerebral Atherosclerosis in the Elderly
NCT07445581Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Tanhuo decoction in acute coronary syndrome (ACS) and cerebral atherosclerosis (2 arms). Primary endpoints: White blood cell count at 1 month, Neutrophil count at 1 month and 7 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Tanhuo decoction
03
Conditions
acute coronary syndrome (ACS)cerebral atherosclerosis
Beyond the preview
Go deeper on NCT07445581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445581.